GLP-1 Daily: Ozempic & Wegovy News
Judge Lets Lilly Keep Its Zepbound-vs-Wegovy Ads Running; South Korea Puts Obesity Drugs Up for Insurance Review; Dr. Reddy's Targets a November Semaglutide Restart
Tuesday, October 27, 2026 · 7 min
A federal judge on Monday refused Novo Nordisk's bid to halt Eli Lilly's comparative weight-loss ads while the suit continues, and South Korea's health minister put obesity drugs up for a managed-insurance review at a hearing that exposed ignored prescribing alerts. Plus, generic semaglutide maker Dr. Reddy's aims to restart supply in November if validation succeeds.
Listen
Show notes
A federal judge on Monday refused Novo Nordisk's bid to halt Eli Lilly's comparative weight-loss ads while the suit continues, and South Korea's health minister put obesity drugs up for a managed-insurance review at a hearing that exposed ignored prescribing alerts. Plus, generic semaglutide maker Dr. Reddy's aims to restart supply in November if validation succeeds.
In this episode
- US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk — StreetInsider
“Quraishi called Novo Nordisk's claim of irreparable harm "inadequate to warrant the extraordinary relief it seeks." The judge ruled after a two-day hearing in late August.”
- Korea Weighs Putting Obesity Drugs Under Health Insurance Controls - Seoul Economic Daily — Park Hong-yong
“The managed benefit scheme brings non-reimbursed items at risk of overtreatment into the national health insurance system so that prices and treatment standards can be managed. It sets the patient co-payment rate at 95%, aiming to curb indiscriminate use of medical services…”
- Dr Reddy's Plans 6-7 Million Semaglutide Pens by March — Drew Thornley
“Dr Reddy's Laboratories expects to relaunch generic semaglutide in Canada in November and has kept its guidance of 6 million to 7 million pens across 10 approved markets between November and March, with Canada taking most of the volume, Narasimham told Moneycontrol in an…”